Neuren Pharmaceuticals Limited announced changes to its leadership team. In response to the changes, the company has realigned its core resources to better respond to the needs of shareholders as well as strategic partners and the FDA. The company has consolidated its clinical development in the US and has augmented its team in Australia with the addition of Jon Pilcher as Chief Financial Officer and Company Secretary, and more recently, with the addition of James Shaw as Chief Operating Officer.

James holds a Bachelor of Science from the UK as well as a Master of Business Administration from Australia. He has spent the last ten years with global Clinical Research organizations including Quintiles, where he held senior roles in both Clinical Operations and Business Development. With a significantly broader therapeutic focus and clinical trial portfolio, the demand for scientific and regulatory oversight and guidance has likewise increased.

In response, Larry Glass, who has served as Neuren's CEO since 2009, will assume the role of Chief Science Officer, responsible for Neuren's scientific and regulatory strategies, management of relationships with key stakeholders such as the US Army, the International Rett Syndrome Foundation and regulatory authorities, as well as interaction with the broader scientific and pharmaceutical industry communities. Larry is the chief architect of Neuren's chronic neurodevelopmental programme as well as the lead in its relationship with the US Army. Larry will continue to serve as an executive director of Neuren Pharmaceuticals Limited as he takes on this new role.

Dr. John Holaday advised the company of his resignation as a nonexecutive director effective 30 August 2013, due to other business commitments. John has been a director of Neuren since 2009.